{"ticker": {"uuid": "89aaa90e-eae8-4beb-9a7c-9bae3257fe88", "symbol": "BLRX", "name": "BioLineRx Ltd.", "exchange": "TLV", "country": "IL", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Enterprise value to EBITDA forward of BioLineRX Ltd. \u2013 TASE:BLRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQNWkzem9oS0JPYXVPQ3hHV0VDa05UcVZxWHZfcThXVEh6YUJXN2F4N1VyUjB3NnFGMy1hT05BbjFzLXVEWXZuUkZQNVc3bEhJZFRueldaV2h6ZlZKdkhoZGJjcFNwdDdLS2x5dDdoUG96ZWR5cDVrYS1QTm1ZY0pvVThSQmQwS2FmZ1lvbGtMdHVWTDhiN2lla3ZEQ3JZb1BSOXRaQlBOYkVsa2c?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T07:35:22+00:00", "published_display": "10 Jul 2026 07:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (NASDAQ: BLRX) reports GLIX1-PARP synergy in ovarian cancer model", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOZjFkc0N0SWhvX3U5cDAydm9USV9lamxRUWN0c08yeUh1SWw2WFl6bGN1VnVQcEdObkl5aFRhel9Ec3lTZi1KcjhtZzVKaUFfdEl0Vzg1c1BYRGdRVjlPcjhFR2IwSk9yeDJYWjZtMFRlM2VQVlJxdlRKNHY2TG8tSE9odjBROEc2SkVDOVdhNklqd3RBelhYMDI4dXVkczROMVdkUUc2dWZwaDZRdTRmdA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx\u2019s ovarian cancer data shows GLIX1 can boost PARP drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOb2wyeC1UY29NeEcxVG9ZSmxRelVnVlIycC1fNTRkcEgyWFIyMlFiX2F2SFZ4Ymw0TnVlNi1jUGJua0liZ2hHMmZzcXVmWjl6Z29JOEtuRVVXYXNOR3pzRUpjN1ZsOVlaZ3plRzJuenU5R0FiTHNZMjcxM1laWXhINXRNeUYyTDNQeFNBdzVRWnBpNzdNUWR3Y3JKQU9SVTJNUVQ1Sm1Za0c0Nm1DZDZwMWg4Yw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Advances 1.94% as It Approaches Key Resistance at $3.32 - Standard Deviation", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOQ0xSNEt6dGc1aWZma0FrVWxpWFRTZjNOdGFJQWltcFlMZW9RdDFteWdCMjVtT3JkYU5tam5wQ2FBaU5HVlpNNEdGUVhNcTBfQS1iSmxzRkdPVl8wbVdsODFVX2g0RzBsN1FDclEwR0RXRGlLR2hjenJncTNJVkZrVGFaV2V6aWphRTcwcmxYWFNId3hhNmFKR0NuWk5pblo5eHVjR2xESnJIMEx6VDZn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Surges 6.5%: Breaking Out or Approaching Resistance? - Jelly Roll Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNX3lsMVVzVTFhM1lHOGNucG14R0NWQmtzdDlpaHJUMnJiZWt5SkhzX3NJRUxYZ2h1WUZVSkU3c3I5SXZ0ZWJYVWFiOXNiXzlHcVo0RnFqbWF3QXRXRjRDMXN3LTNUZzVjMUlXLURpc3YtbHQtZEpqNFd2eTE1UDZOczlYX1A2Vjh3RmxrMEVaRUJoNVJxV2l0dFFFeElvcER0NlhzYXFtOXhyUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOLXNlS1VDOWJJbjJtalFHYnN6VGJXcTBZNWNXT1RjZTFkMnRXbnFYRDVoTHJFaG5RQ09UR0Q1enlZVWRtTVo3U1czeE5ydE41NTFoXzdCOS1XNTI3dWxmU3Y5Vnp4a1pLNnMwYmpYWk45ZXZMczFWRU9ZOUdnbm9XTkwwWFFLeXcyb0ZPempaNmR0RkEzeXRaWFJYd3VmbF9ja1BoMW5yOUYtRDExMmxrTkNmOUJCZ0ZPWmRuSEFtMnVZa0JVeHdROGhMOUJMT0QyWDV0cWhxZw?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOTXlwc0Q2d3dta2toNWZDTnZPNUhxWnctSHktaVlqTDU0NElBTTZ5U2VVa3kzUlotcUF5dDJOaG9WdFFZdEZOOUJrRGlwSGdQRW9sRFpwbXdVdjdmYlN1dnlHamk3SVpmRlhxenVkclNrc2pnbHlZTUtXSFR2RnE5MlY4THo1ZkpIMEZRYm1uckFvR2tQTHJJbGoxdDFwQ1dMRkhrdkhONi1DSEE?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Surges Over 9%: Biotech Stock Breaks Above Key Support Level - Sector ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPZFcyUmhFNjlCc2xGczFIb0hLRnFmRFo1cTdneG93SW1jaUpfWGIycTgxeG5XSUY4c0lfUFkzNTFJdXJHWFFTbzVxU0hPZV9pSXQxRDJ5WXc4Y3FNS0VqRWZzcTNqak1sT2M0YzNnaHE3VDJodTM4bnlETU5kSTgtQnMxbE1aSHg1SlhUS2U5Tk5EY004VjMyQzhmdmpMOC1UczFJT1owVXU5RVVwcHhnTW90czJWdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx lines up May 27 results call with CEO at 8:30 a.m.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNOC1SQ2VtWDlYWjNCcTczYi1wd1B3RGxYZU5FcVMxYmlYNFY0cFpaTjJZd01FWjFNc0dGdDNyamNLYTNBYllNSElVN1AzQWFnSEhuaEhlWF84OUcxZll2VF9VYmN4TG0yeUt4QjRZU3JISVN6ZlJTMXVPZWZWeUZ2cl9Pd3I1R1ExQlR5QldLekhaZDBpc2dhNW9mdC1ONEl2Q2R5RTdlN1pzQWl5OVFON3N5SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Reports 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxORWVIQ2pPN0lvQTVFQjBmWWVESTI1VElhdXY4MkllRld2SXcxQ2oydnZ1dV9Rd2lobFJTWF9UZlBsWnA5Z2g5SXVXM3hRbzRTMDlVTS1tbGlRQ3JJVVRxYU5pemZrR1k0VEk5MTB2Y1JlWERDeGxQSHRVSjV0aEx1dC1EQnlhN3V1d1VnSHUydGllS3FLOVF1SHF4TWYzVmV0b1lXVTNvdjVrUUNoaDl3SjRhSlZSMFF5RFAtVi1TZFFlZ0wt?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPTVVLS0xLRFpXcDlRUlloLWFBV2J4Z0Q0SllfbjQtbXB1YkVXZFVGSDVLZUp6OG9jQ3o1NW1IdFVBQ0Y5dmFYV2ZMUVowSHExLU8xbl8taG5BaG9fV09oYkZYRkVDQTVHODFXN3BoNV9jNWliX2hTcFlsV0swMnRKRHBXTllfSXE0VFM5bGtoU3l0QlBZSVB3V05RVkRTN0lHLWlfUkZQaFl0bmVGSUVQUmZaVVhaR1BEbTJBRDlkUzN5WVJEV1hpcmNkcml1S1NRaWJNUV92SQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biolinerx (BLRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9IelhXR3VfVGRvYjdnRDZTOFFtMzJKZEwwRUo2aFo2aW9Za0RHZnhzX1luaS1qd01SNjZFYVUzMkdRNHJ4WDFlbk5VOXhtZW5Zd3Rz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:26:01+00:00", "published_display": "25 Apr 2025 00:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA\u00ae (motixafortide) through Gamida Cell Ltd.", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxQVWt0ZVRYR09seUZST2haQ1laYjRaTlNuYlpsanhfeGJRdlNnMW1uRjV0NWNQLWlwNEk2LVdyQ1pMWWFNZ0R3dF9IMTlrbk9QNmlKVDFZV2lqcHBtWGJVbHRiZlkwenp3cjhWYjNRMk1JMkJpSlFmUjhkQnpfa3lWSU9oSEdmODdGVFdOZk9lc3QwX1J3bU51OHlCS0ZnTmk1eS05QmJKemJtSTJvWFBOcVFSeHRfZFB4aTc3cklmdnpKWkpXbXRIcTBJWnZCWDd4ZlQxS2c2NnVQLTFDTS1TOElVaDVURlV4WUJvaFM2N1NSajF3UVZjZkJzOUstYXdWdGhfM3FhczlGdnZfVDhNTDZJVQ?oc=5", "source_name": "PR Newswire", "published_at": "2024-11-21T08:00:00+00:00", "published_display": "21 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for BioLineRx (BLRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9lOHdlM0tGNkJiWFVvRlAxdGY3aHZ0cUxRMFFWQUlVczNUOHYxTzgzNHQzdmotMHMtUDBLVWxTMFAtc0dTaFJOTmtnYWhUcHlHT2J3Mk5DSHJod05ZbFQ4MDI3bWtCMkxjS1JuRW9YcV9OTU1zX2d0Wg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-08-16T11:27:33+00:00", "published_display": "16 Aug 2022 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biolinerx Stock Price Forecast. Should You Buy BLRX?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE5ucFpqMjN4OEloQW90dEtac0I3eEZMVGNZdTBRUzRtOWxQWm16dGpSMDJWaV9DZDJxbFFMZUY3N2wyM0tqaWRENw?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-01T17:10:19+00:00", "published_display": "01 Dec 2020 17:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to EBITDA forward of BioLineRX Ltd. \u2013 TASE:BLRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQNWkzem9oS0JPYXVPQ3hHV0VDa05UcVZxWHZfcThXVEh6YUJXN2F4N1VyUjB3NnFGMy1hT05BbjFzLXVEWXZuUkZQNVc3bEhJZFRueldaV2h6ZlZKdkhoZGJjcFNwdDdLS2x5dDdoUG96ZWR5cDVrYS1QTm1ZY0pvVThSQmQwS2FmZ1lvbGtMdHVWTDhiN2lla3ZEQ3JZb1BSOXRaQlBOYkVsa2c?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T07:35:22+00:00", "published_display": "10 Jul 2026 07:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (NASDAQ: BLRX) reports GLIX1-PARP synergy in ovarian cancer model", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOZjFkc0N0SWhvX3U5cDAydm9USV9lamxRUWN0c08yeUh1SWw2WFl6bGN1VnVQcEdObkl5aFRhel9Ec3lTZi1KcjhtZzVKaUFfdEl0Vzg1c1BYRGdRVjlPcjhFR2IwSk9yeDJYWjZtMFRlM2VQVlJxdlRKNHY2TG8tSE9odjBROEc2SkVDOVdhNklqd3RBelhYMDI4dXVkczROMVdkUUc2dWZwaDZRdTRmdA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx\u2019s ovarian cancer data shows GLIX1 can boost PARP drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOb2wyeC1UY29NeEcxVG9ZSmxRelVnVlIycC1fNTRkcEgyWFIyMlFiX2F2SFZ4Ymw0TnVlNi1jUGJua0liZ2hHMmZzcXVmWjl6Z29JOEtuRVVXYXNOR3pzRUpjN1ZsOVlaZ3plRzJuenU5R0FiTHNZMjcxM1laWXhINXRNeUYyTDNQeFNBdzVRWnBpNzdNUWR3Y3JKQU9SVTJNUVQ1Sm1Za0c0Nm1DZDZwMWg4Yw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Advances 1.94% as It Approaches Key Resistance at $3.32 - Standard Deviation", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOQ0xSNEt6dGc1aWZma0FrVWxpWFRTZjNOdGFJQWltcFlMZW9RdDFteWdCMjVtT3JkYU5tam5wQ2FBaU5HVlpNNEdGUVhNcTBfQS1iSmxzRkdPVl8wbVdsODFVX2g0RzBsN1FDclEwR0RXRGlLR2hjenJncTNJVkZrVGFaV2V6aWphRTcwcmxYWFNId3hhNmFKR0NuWk5pblo5eHVjR2xESnJIMEx6VDZn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Surges 6.5%: Breaking Out or Approaching Resistance? - Jelly Roll Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNX3lsMVVzVTFhM1lHOGNucG14R0NWQmtzdDlpaHJUMnJiZWt5SkhzX3NJRUxYZ2h1WUZVSkU3c3I5SXZ0ZWJYVWFiOXNiXzlHcVo0RnFqbWF3QXRXRjRDMXN3LTNUZzVjMUlXLURpc3YtbHQtZEpqNFd2eTE1UDZOczlYX1A2Vjh3RmxrMEVaRUJoNVJxV2l0dFFFeElvcER0NlhzYXFtOXhyUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOLXNlS1VDOWJJbjJtalFHYnN6VGJXcTBZNWNXT1RjZTFkMnRXbnFYRDVoTHJFaG5RQ09UR0Q1enlZVWRtTVo3U1czeE5ydE41NTFoXzdCOS1XNTI3dWxmU3Y5Vnp4a1pLNnMwYmpYWk45ZXZMczFWRU9ZOUdnbm9XTkwwWFFLeXcyb0ZPempaNmR0RkEzeXRaWFJYd3VmbF9ja1BoMW5yOUYtRDExMmxrTkNmOUJCZ0ZPWmRuSEFtMnVZa0JVeHdROGhMOUJMT0QyWDV0cWhxZw?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOTXlwc0Q2d3dta2toNWZDTnZPNUhxWnctSHktaVlqTDU0NElBTTZ5U2VVa3kzUlotcUF5dDJOaG9WdFFZdEZOOUJrRGlwSGdQRW9sRFpwbXdVdjdmYlN1dnlHamk3SVpmRlhxenVkclNrc2pnbHlZTUtXSFR2RnE5MlY4THo1ZkpIMEZRYm1uckFvR2tQTHJJbGoxdDFwQ1dMRkhrdkhONi1DSEE?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx (BLRX) Surges Over 9%: Biotech Stock Breaks Above Key Support Level - Sector ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPZFcyUmhFNjlCc2xGczFIb0hLRnFmRFo1cTdneG93SW1jaUpfWGIycTgxeG5XSUY4c0lfUFkzNTFJdXJHWFFTbzVxU0hPZV9pSXQxRDJ5WXc4Y3FNS0VqRWZzcTNqak1sT2M0YzNnaHE3VDJodTM4bnlETU5kSTgtQnMxbE1aSHg1SlhUS2U5Tk5EY004VjMyQzhmdmpMOC1UczFJT1owVXU5RVVwcHhnTW90czJWdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx lines up May 27 results call with CEO at 8:30 a.m.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNOC1SQ2VtWDlYWjNCcTczYi1wd1B3RGxYZU5FcVMxYmlYNFY0cFpaTjJZd01FWjFNc0dGdDNyamNLYTNBYllNSElVN1AzQWFnSEhuaEhlWF84OUcxZll2VF9VYmN4TG0yeUt4QjRZU3JISVN6ZlJTMXVPZWZWeUZ2cl9Pd3I1R1ExQlR5QldLekhaZDBpc2dhNW9mdC1ONEl2Q2R5RTdlN1pzQWl5OVFON3N5SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Reports 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxORWVIQ2pPN0lvQTVFQjBmWWVESTI1VElhdXY4MkllRld2SXcxQ2oydnZ1dV9Rd2lobFJTWF9UZlBsWnA5Z2g5SXVXM3hRbzRTMDlVTS1tbGlRQ3JJVVRxYU5pemZrR1k0VEk5MTB2Y1JlWERDeGxQSHRVSjV0aEx1dC1EQnlhN3V1d1VnSHUydGllS3FLOVF1SHF4TWYzVmV0b1lXVTNvdjVrUUNoaDl3SjRhSlZSMFF5RFAtVi1TZFFlZ0wt?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPTVVLS0xLRFpXcDlRUlloLWFBV2J4Z0Q0SllfbjQtbXB1YkVXZFVGSDVLZUp6OG9jQ3o1NW1IdFVBQ0Y5dmFYV2ZMUVowSHExLU8xbl8taG5BaG9fV09oYkZYRkVDQTVHODFXN3BoNV9jNWliX2hTcFlsV0swMnRKRHBXTllfSXE0VFM5bGtoU3l0QlBZSVB3V05RVkRTN0lHLWlfUkZQaFl0bmVGSUVQUmZaVVhaR1BEbTJBRDlkUzN5WVJEV1hpcmNkcml1S1NRaWJNUV92SQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biolinerx (BLRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9IelhXR3VfVGRvYjdnRDZTOFFtMzJKZEwwRUo2aFo2aW9Za0RHZnhzX1luaS1qd01SNjZFYVUzMkdRNHJ4WDFlbk5VOXhtZW5Zd3Rz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:26:01+00:00", "published_display": "25 Apr 2025 00:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA\u00ae (motixafortide) through Gamida Cell Ltd.", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxQVWt0ZVRYR09seUZST2haQ1laYjRaTlNuYlpsanhfeGJRdlNnMW1uRjV0NWNQLWlwNEk2LVdyQ1pMWWFNZ0R3dF9IMTlrbk9QNmlKVDFZV2lqcHBtWGJVbHRiZlkwenp3cjhWYjNRMk1JMkJpSlFmUjhkQnpfa3lWSU9oSEdmODdGVFdOZk9lc3QwX1J3bU51OHlCS0ZnTmk1eS05QmJKemJtSTJvWFBOcVFSeHRfZFB4aTc3cklmdnpKWkpXbXRIcTBJWnZCWDd4ZlQxS2c2NnVQLTFDTS1TOElVaDVURlV4WUJvaFM2N1NSajF3UVZjZkJzOUstYXdWdGhfM3FhczlGdnZfVDhNTDZJVQ?oc=5", "source_name": "PR Newswire", "published_at": "2024-11-21T08:00:00+00:00", "published_display": "21 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for BioLineRx (BLRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9lOHdlM0tGNkJiWFVvRlAxdGY3aHZ0cUxRMFFWQUlVczNUOHYxTzgzNHQzdmotMHMtUDBLVWxTMFAtc0dTaFJOTmtnYWhUcHlHT2J3Mk5DSHJod05ZbFQ4MDI3bWtCMkxjS1JuRW9YcV9OTU1zX2d0Wg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-08-16T11:27:33+00:00", "published_display": "16 Aug 2022 11:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biolinerx Stock Price Forecast. Should You Buy BLRX?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE5ucFpqMjN4OEloQW90dEtac0I3eEZMVGNZdTBRUzRtOWxQWm16dGpSMDJWaV9DZDJxbFFMZUY3N2wyM0tqaWRENw?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-01T17:10:19+00:00", "published_display": "01 Dec 2020 17:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 74, "total_relevant": 15, "sentiment_summary": {"positive": 3, "negative": 0, "neutral": 12, "score": 53, "total": 15, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 4.95, "count": 9}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}], "positive_events": 3, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.01, "latest_week": "2026-07-17", "one_week_move": -6.7, "four_week_move": -12.5, "twelve_week_move": 7.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.211555, "market_dynamics_buy_signal": false, "relative_strength": -29.01157, "fair_value_gap": -89.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 27.9298, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.7% over one week, -12.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 4}, {"label": "PR Newswire", "count": 4}, {"label": "dars.gov.et", "count": 3}, {"label": "TradingView", "count": 1}, {"label": "Market source", "count": 1}, {"label": "Zacks Investment Research", "count": 1}, {"label": "StockInvest.us", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 15}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 9}, {"label": "Earnings", "count": 4}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "15", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.7% over one week, -12.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to EBITDA forward of BioLineRX Ltd. \u2013 TASE:BLRX"}], "updated_at": "2026-07-22T03:59:41.816924+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}